
Risk stratification in AML
Quiz by Sadeq K. Ali Al-Salait
Tag the questions with any skills you have. Your dashboard will track each student's mastery of each skill.
Which cytogenetic abnormality is classified as favorable risk in AML according to ELN 2022?
Which of the following co-occurring mutations in CBF leukemias is controversial for reclassifying t(8;21) AML to a higher-risk group?
Which gene mutation is associated with a favorable prognosis in AML when biallelic but lost its prognostic weight in ELN 2022 unless it involves the bZIP domain?
Which of the following is NOT considered an adverse-risk cytogenetic abnormality in ELN 2022?
Which mutation is frequently co-occurring with NPM1 and FLT3-ITD to identify a subgroup with poor outcomes?
Which simple parameter is helpful for identifying patients at higher risk of early mortality in AML?
Which MRD detection method is recommended for NPM1-mutated AML according to ELN 2021 guidelines?
Which of the following mutations is LEAST suitable for MRD monitoring due to its association with clonal hematopoiesis?
At which time point is MRD assessment recommended in peripheral blood for NPM1-mutated AML after chemotherapy?
Which of the following scenarios warrants a change in treatment based on MRD findings?
Which non-coding RNA molecule has been associated with predicting AML outcome independently of ELN risk stratification?
Higher expression of which miRNA is associated with shorter overall survival in AML?
Which epigenetic modifier is frequently mutated in AML and associated with DNA hypermethylation?
Which protein is involved in chemotherapy resistance and is the product of the MDR1 gene?
BH3 profiling predicts cellular dependence on which anti-apoptotic protein?
A 40-year-old patient with AML is found to have t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 and a co-occurring c-KIT mutation. How would this patient be risk-stratified according to ELN 2022?
A patient with NPM1-mutated AML achieves complete remission after induction but has detectable MRD (0.5% mutant copies) after consolidation. What is the recommended action?
Which of the following clonal architecture features is associated with poorer prognosis in AML?
Which multi-omic approach is likely to shed light on clonal architecture and functional diversity in AML?
Which mutation pair is synergistic and associated with clonal dominance and poor prognosis?